絞り込み

16638

広告

Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.

著者 Ting J , Tien Ho P , Xiang P , Sugay A , Abdel-Sattar M , Wilson L
Value Health.2015 Sep ; 18(6):774-782.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (267view , 0users)

Full Text Sources

Medical

Miscellaneous

To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial growth factor receptor mutation-positive non-small-cell lung cancer in the United States. We also assessed the expected benefit of further research to reduce uncertainty regarding which treatment is optimal.
PMID: 26409604 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード